PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21161015-4	2010	Three years after the start of additional adefovir treatment, hepatocellular carcinoma (HCC) was detected and the patient underwent a successful hepatectomy.	adefovir	42-50	HCC	Homo sapiens	62-92	
21161015-5	2010	Our findings suggest that the addition of adefovir to ongoing lamivudine therapy cannot completely suppress hepatocarcinogenesis, but is useful for improving liver function in patients with lamivudine-resistant HBV-related cirrhosis, allowing HCC surgery.	adefovir	42-50	HCC	Homo sapiens	243-246	
19788684-1	2010	AIM: To identify factors for the development of hepatocellular carcinoma (HCC) in the patients who receive adefovir add-on lamivudine for treatment of lamivudine-resistant hepatitis B virus (HBV) mutants.	adefovir	107-115	HCC	Homo sapiens	74-77	
19788684-9	2010	HCC developed more frequently in the patients with than without cirrhosis at the start of adefovir (10/59 [16.9%] vs. 8/188 [4.3%], P = 0.002).	adefovir	90-98	HCC	Homo sapiens	0-3	
19788684-10	2010	CONCLUSION: HCC can develop in cirrhotic patients receiving adefovir add-on lamivudine.	adefovir	60-68	HCC	Homo sapiens	12-15